(INGN) Inogen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45780L1044

Oxygen Concentrators, Accessories, Rental

Stock: Health Care Equipment
Age 11.9y
MCap 170m
Avg Vol 153K (1.01M USD)
Beta 0.902
Volatility 64.21%

EPS (Earnings per Share)

EPS (Earnings per Share) of INGN over the last years for every Quarter: "2020-12": -0.23, "2021-03": -0.03, "2021-06": 0.22, "2021-09": 0.53, "2021-12": -1.01, "2022-03": -0.62, "2022-06": -0.15, "2022-09": -0.42, "2022-12": -0.2, "2023-03": -0.88, "2023-06": -0.42, "2023-09": -0.55, "2023-12": -1.14, "2024-03": -0.62, "2024-06": -0.24, "2024-09": -0.25, "2024-12": -0.24, "2025-03": -0.11, "2025-06": -0.15, "2025-09": -0.2, "2025-12": 0,
EPS CAGR: 22.47%
EPS Trend: 46.4%
Last SUE: 1.31
Qual. Beats: 1

Revenue

Revenue of INGN over the last years for every Quarter: 2020-12: 73.978, 2021-03: 86.932, 2021-06: 101.563, 2021-09: 93.105, 2021-12: 76.403, 2022-03: 80.385, 2022-06: 103.376, 2022-09: 105.389, 2022-12: 88.091, 2023-03: 72.162, 2023-06: 83.635, 2023-09: 83.967, 2023-12: 75.896, 2024-03: 78.025, 2024-06: 88.765, 2024-09: 88.834, 2024-12: 80.081, 2025-03: 82.28, 2025-06: 92.277, 2025-09: 92.39, 2025-12: null,
Rev. CAGR: 5.20%
Rev. Trend: 3.6%
Last SUE: 0.07
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 64.2%
Value at Risk 5%th 87.1%
Relative Tail Risk -17.59%
Reward TTM
Sharpe Ratio -0.90
Alpha -54.13
CAGR/Max DD -0.41
Character TTM
Hurst Exponent 0.461
Beta 0.902
Beta Downside 0.611
Drawdowns 3y
Max DD 83.81%
Mean DD 66.15%
Median DD 68.96%

Description: INGN Inogen January 01, 2026

Inogen, Inc. (NASDAQ: INGN) designs, manufactures, and markets portable and stationary oxygen concentrators for long-term oxygen therapy (LTOT) in the U.S. and abroad. Its product lineup includes the Inogen One and Rove series of ambulatory concentrators, the stationary Inogen At Home units, the Simeox airway-clearance system, and related accessories, with a rental model that delivers devices directly to patients.

Key metrics that analysts watch include FY2023 revenue of roughly $115 million, a year-over-year increase of about 12%, and an operating margin hovering near 5%, reflecting ongoing investment in R&D and regulatory compliance. The home oxygen market is projected to expand at a 6% CAGR through 2028, driven by an aging population, rising prevalence of chronic obstructive pulmonary disease (COPD), and favorable Medicare reimbursement policies. Competitive pressure from larger players such as Philips Respironics and AirSep underscores the importance of Inogen’s patented pulse-dose technology and its direct-to-patient rental channel.

For deeper quantitative insights, consider reviewing ValueRay’s analyst dashboard.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -25.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.08 > 0.02 and ΔFCF/TA -3.23 > 1.0
NWC/Revenue: 39.99% < 20% (prev 36.24%; Δ 3.74% < -1%)
CFO/TA -0.04 > 3% & CFO -13.3m > Net Income -25.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.14 > 1.5 & < 3
Outstanding Shares: last quarter (26.4m) vs 12m ago 11.19% < -2%
Gross Margin: 46.38% > 18% (prev 0.44%; Δ 4594 % > 0.5%)
Asset Turnover: 113.2% > 50% (prev 108.3%; Δ 4.91% > 0%)
Interest Coverage Ratio: -10.73 > 6 (EBITDA TTM -8.08m / Interest Expense TTM -2.68m)

Altman Z'' (< 1.1 .. > 2.6) -1.03

A: 0.45 (Total Current Assets 203.7m - Total Current Liabilities 64.9m) / Total Assets 307.0m
B: -0.55 (Retained Earnings -168.5m / Total Assets 307.0m)
C: -0.09 (EBIT TTM -28.8m / Avg Total Assets 306.6m)
D: -1.50 (Book Value of Equity -164.7m / Total Liabilities 109.8m)
Total Rating: -1.03= CCC

ValueRay F-Score (Strict, 0-100) 30.24

1. Piotroski: 2.50pt
2. FCF Yield: -38.55%
3. FCF Margin: -7.04%
4. Debt/Equity: 0.09
5. Debt/Ebitda: data missing
6. ROIC - WACC: -20.92%
7. RoE: -13.21%
8. Revenue Trend: 3.61%
9. EPS Trend: 46.35%

What is the price of INGN shares?

As of January 22, 2026, the stock is trading at USD 6.36 with a total of 208,051 shares traded.
Over the past week, the price has changed by -2.15%, over one month by -5.78%, over three months by -25.09% and over the past year by -43.16%.

Is INGN a buy, sell or hold?

Inogen has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold INGN.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the INGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 13 104.4%
Analysts Target Price 13 104.4%
ValueRay Target Price 4.8 -25%

INGN Fundamental Data Overview January 18, 2026

P/S = 0.4889
P/B = 0.8605
P/EG = 3.48
Revenue TTM = 347.0m USD
EBIT TTM = -28.8m USD
EBITDA TTM = -8.08m USD
Long Term Debt = 18.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 18.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.5m USD (from netDebt column, last quarter)
Enterprise Value = 63.4m USD (169.7m + Debt 18.2m - CCE 124.5m)
Interest Coverage Ratio = -10.73 (Ebit TTM -28.8m / Interest Expense TTM -2.68m)
EV/FCF = -2.59x (Enterprise Value 63.4m / FCF TTM -24.4m)
FCF Yield = -38.55% (FCF TTM -24.4m / Enterprise Value 63.4m)
FCF Margin = -7.04% (FCF TTM -24.4m / Revenue TTM 347.0m)
Net Margin = -7.31% (Net Income TTM -25.4m / Revenue TTM 347.0m)
Gross Margin = 46.38% ((Revenue TTM 347.0m - Cost of Revenue TTM 186.1m) / Revenue TTM)
Gross Margin QoQ = 50.82% (prev 44.80%)
Tobins Q-Ratio = 0.21 (Enterprise Value 63.4m / Total Assets 307.0m)
Interest Expense / Debt = 9.67% (Interest Expense 1.76m / Debt 18.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -22.7m (EBIT -28.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.14 (Total Current Assets 203.7m / Total Current Liabilities 64.9m)
Debt / Equity = 0.09 (Debt 18.2m / totalStockholderEquity, last quarter 197.2m)
Debt / EBITDA = 11.08 (negative EBITDA) (Net Debt -89.5m / EBITDA -8.08m)
Debt / FCF = 3.66 (negative FCF - burning cash) (Net Debt -89.5m / FCF TTM -24.4m)
Total Stockholder Equity = 192.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.28% (Net Income -25.4m / Total Assets 307.0m)
RoE = -13.21% (Net Income TTM -25.4m / Total Stockholder Equity 192.1m)
RoCE = -13.69% (EBIT -28.8m / Capital Employed (Equity 192.1m + L.T.Debt 18.2m))
RoIC = -11.84% (negative operating profit) (NOPAT -22.7m / Invested Capital 192.1m)
WACC = 9.08% (E(169.7m)/V(187.9m) * Re(9.24%) + D(18.2m)/V(187.9m) * Rd(9.67%) * (1-Tc(0.21)))
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 2.15%
Fair Price DCF = unknown (Cash Flow -24.4m)
EPS Correlation: 46.35 | EPS CAGR: 22.47% | SUE: 1.31 | # QB: 1
Revenue Correlation: 3.61 | Revenue CAGR: 5.20% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.22 | Chg30d=+0.035 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.16 | Chg30d=+0.200 | Revisions Net=+0 | Growth EPS=+51.5% | Growth Revenue=+8.4%

Additional Sources for INGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle